Company profile: BlueWillow Biologics
1.1 - Company Overview
Company description
- Provider of intranasal vaccine and adjuvant technologies, including an oil-in-water emulsion Intranasal Adjuvant Technology, NE01 adjuvanted intranasal vaccines, the BW-1010 anthrax vaccine candidate, and a therapeutic peanut allergy vaccine, built on the NanoVax platform to elicit mucosal, cellular, and systemic immunity; also focused on topical antiseptic and anti-infective products.
Products and services
- NanoVax Platform: A nanoemulsion-based platform that engineers intranasal vaccines, enhancing antigen delivery and immune response for diverse pathogens and allergens
- Intranasal Adjuvant Technology: A proprietary oil-in-water emulsion adjuvant platform compatible with a wide range of antigens, eliciting robust mucosal, cellular, and systemic immune responses for intranasal vaccination
- NE01 Adjuvanted Vaccines: Spray-delivered intranasal vaccines using the NE01 adjuvant to induce potent mucosal, systemic, and cell-mediated immunity via an intranasal spray device
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BlueWillow Biologics
Cellics Therapeutics
HQ: United States
Website
- Description: Provider of biomimetic nanomedicines based on cellular nanosponges—nanoparticles coated with cell membranes—to bind and neutralize bacterial toxins, cytokines, and viruses. Products include CTI-005, a red blood cell nanosponge for MRSA pneumonia, and CTI-111, a macrophage nanosponge for sepsis that absorbs and neutralizes toxins and inflammatory cytokines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellics Therapeutics company profile →
Suono Bio
HQ: United States
Website
- Description: Provider of ultrasound-mediated drug delivery platforms enabling ultra-rapid delivery of small molecules, biologics, and nucleic acids to the gastrointestinal tract and directly into cells without encapsulation; offerings include Ultrasonic Enhanced Delivery and SuonoCalm for treating inflammatory conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Suono Bio company profile →
Incline Therapeutics
HQ: United States
Website
- Description: Provider of hospital-focused specialty pharmaceutical solutions, developing IONSYS (fentanyl iontophoretic transdermal system), a pharmaceutical device for the treatment of post-operative pain in hospital settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Incline Therapeutics company profile →
MannKind
HQ: United States
Website
- Description: Provider of inhaled and wearable therapeutic products and platforms for diabetes and pulmonary diseases, including Afrezza (inhaled insulin), Tyvaso DPI (treprostinil for PAH and PH-ILD), Clofazimine Inhalation Suspension (for NTM lung disease), Nintedanib DPI (for pulmonary fibrotic diseases), V-Go (wearable insulin delivery), and Technosphere Technology for dry powder inhalation formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MannKind company profile →
Kaleo
HQ: United States
Website
- Description: Provider of specialty pharmaceutical combination drug/device products and auto-injectors, including the Aerio gas-powered auto-injector platform (single, dual container, dual chamber); AUVI-Q and ALLERJECT epinephrine devices for severe allergic reactions; Naloxone Auto-Injector 10 mg for military and chemical incident responders; Pralidoxime Chloride Auto-Injector; and a patient assistance program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kaleo company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BlueWillow Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BlueWillow Biologics
2.2 - Growth funds investing in similar companies to BlueWillow Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BlueWillow Biologics
4.2 - Public trading comparable groups for BlueWillow Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →